Continued Spending on Research and Development Activities
First written in FY2017-Q1. 21 of 33 entries say "Restated". Latest entry: FY2027-H1.
3 other companies' latest entry also says "Advanced".
- FY2027-H1AdvancedAnnual report
「The Group's research and development expenditure during the interim consolidated accounting period was ¥7.620 billion.」
Research and development expenditure increased from ¥7.516 billion in the same period of the previous year to ¥7.620 billion. The company stated that there were no material changes in its research and development activities. - FY2026Decline in research and development expenditure and research personnelAnnual report
「The group’s R&D expenditure for the consolidated fiscal year was ¥14,768 million, with 849 R&D personnel. During the consolidated fiscal year, 377 patents were published following domestic applications, 173 patents were published following international applications, and 308 patents, including utility models, were registered domestically.」
R&D expenditure was ¥14,768 million and R&D personnel numbered 849, down from ¥14,887 million and 867 personnel in the previous fiscal year. The company also disclosed 377 domestically published patents, 173 internationally published patents and 308 domestic registrations. - FY2026-H1RestatedAnnual report
「The group’s total R&D expenditure for the current interim consolidated accounting period was ¥7,516 million. There were no significant changes in the status of the group’s R&D activities during the current interim consolidated accounting period.」
The company recorded R&D expenditure of ¥7,516 million and stated that there had been no significant changes in the status of its R&D activities. - FY2025Decrease in R&D expenditure; increase in R&D personnelAnnual report
「The group’s R&D expenditure for the consolidated fiscal year was ¥14,887 million, with 867 R&D personnel. During the consolidated fiscal year, 181 patents were published following domestic applications, 203 patents were published following international applications, and 428 patents, including utility models, were registered domestically.」
R&D expenditure was ¥14,887 million, with 867 R&D personnel, 181 domestically published patents, 203 internationally published patents and 428 domestically registered patents. - FY2025-H1RestatedAnnual report
「The group’s total R&D expenditure for the current interim consolidated accounting period was ¥7,435 million. There were no significant changes in the status of the group’s R&D activities during the current interim consolidated accounting period.」
The company recorded R&D expenditure of ¥7,435 million and stated that there had been no significant changes in the status of its R&D activities. - FY2024AdvancedAnnual report
「The group’s R&D expenditure for the consolidated fiscal year was ¥15,162 million, with 864 R&D personnel. During the consolidated fiscal year, 196 patents were published following domestic applications, 215 patents were published following international applications, and 291 patents, including utility models, were registered domestically.」
The company disclosed R&D expenditure of ¥15,162 million, 864 R&D personnel, and the numbers of domestic and international patents published and domestic patents registered. R&D expenditure, R&D personnel and domestic patent registrations increased from the previous fiscal year. - FY2024-Q3AdvancedAnnual report
「The group’s total R&D expenditure for the third quarter of the current consolidated cumulative period was ¥11,518 million.」
R&D expenditure for the third quarter of the consolidated cumulative period was ¥11,518 million, up from ¥11,326 million in the same period of the previous year. - FY2024-Q2RestatedAnnual report
「The group’s total R&D expenditure for the second quarter of the current consolidated cumulative period was ¥7,803 million. There were no significant changes in the status of the group’s R&D activities during the second quarter of the current consolidated cumulative period.」
The company recorded R&D expenditure of ¥7,803 million and stated that there had been no significant changes in the status of its R&D activities. - FY2024-Q1RestatedAnnual report
「The group’s total R&D expenditure for the first quarter of the current consolidated cumulative period was ¥3,845 million. There were no significant changes in the status of the group’s R&D activities during the first quarter of the current consolidated cumulative period.」
The company disclosed first-quarter R&D expenditure of ¥3,845 million and stated that there had been no significant changes in the status of its R&D activities. - FY2023AdvancedAnnual report
「The group’s R&D expenditure for the consolidated fiscal year was ¥14,931 million, with 853 R&D personnel. During the consolidated fiscal year, 185 patents were published following domestic applications, 292 patents were published following international applications, and 229 patents, including utility models, were registered domestically.」
The company disclosed R&D expenditure of ¥14,931 million, 853 R&D personnel, and the numbers of domestic and international patent applications published and domestic patents registered. - FY2023-Q3AdvancedAnnual report
「The group’s total R&D expenditure for the third quarter of the current consolidated cumulative period was ¥11,326 million.」
R&D expenditure for the third quarter of the consolidated cumulative period was ¥11,326 million, up from ¥10,895 million in the same period of the previous year. - FY2023-Q2RestatedAnnual report
「The group’s total R&D expenditure for the second quarter of the current consolidated cumulative period was ¥7,461 million.」
The company recorded R&D expenditure of ¥7,461 million and disclosed continued spending on R&D activities. - FY2023-Q1AdvancedAnnual report
「The group’s total R&D expenditure for the first quarter of the current consolidated cumulative period was ¥3,876 million.」
R&D expenditure was ¥3,876 million, up from ¥3,766 million in the same period of the previous year. The disclosure also noted a significant change involving the reorganisation of the research and new business development structure. - FY2022-Q3RestatedAnnual report
「The Group's total research and development expenditure for the nine months ended the third quarter was ¥10.895 billion.」
Disclosed research and development expenditure of ¥10.895 billion for the nine months ended the third quarter, with no material change in research and development activities. - FY2022-Q2RestatedAnnual report
「The Group's total research and development expenditure for the six months ended the second quarter was ¥7.424 billion. There was no material change in the status of the Group's research and development activities during the six months ended the second quarter.」
Disclosed research and development expenditure of ¥7.424 billion for the six months ended the second quarter, with no material change in research and development activities. - FY2022-Q1RestatedAnnual report
「The Group's total research and development expenditure for the three months ended the first quarter was ¥3.766 billion. There was no material change in the status of the Group's research and development activities during the three months ended the first quarter.」
Disclosed research and development expenditure of ¥3.766 billion for the three months ended the first quarter, with no material change in research and development activities. - FY2021AdvancedAnnual report
「For the fiscal year, the Group's total research and development expenditure was ¥14.736 billion and it had 849 research personnel. During the fiscal year, 483 patents were filed in Japan, and 182 patents were registered in Japan, including utility models.」
Research and development expenditure was ¥14.736 billion, with 849 research personnel, 483 domestic patent applications and 182 registrations. These figures increased from the previous fiscal year's ¥14.562 billion in research and development expenditure, 807 research personnel, 214 applications and 97 registrations. - FY2021-Q3RestatedAnnual report
「The Group's total research and development expenditure for the nine months ended the third quarter was ¥11.088 billion.」
Disclosed research and development expenditure of ¥11.088 billion for the nine months ended the third quarter, with no material change in research and development activities. - FY2021-Q2RestatedAnnual report
「The Group's total research and development expenditure for the six months ended the second quarter was ¥7.429 billion. There was no material change in the status of the Group's research and development activities during the six months ended the second quarter.」
Disclosed research and development expenditure of ¥7.429 billion for the six months ended the second quarter, with no material change in research and development activities. - FY2021-Q1RestatedAnnual report
「The Group's total research and development expenditure for the three months ended the first quarter was ¥3.813 billion. There was no material change in the status of the Group's research and development activities during the three months ended the first quarter.」
Disclosed research and development expenditure of ¥3.813 billion, with no material change in research and development activities. - FY2020-Q2RestatedAnnual report
「The Group's total research and development expenditure for the six months ended the second quarter was ¥7.273 billion. There was no material change in the status of the Group's research and development activities during the six months ended the second quarter.」
Disclosed research and development expenditure of ¥7.273 billion, with no material change in research and development activities. - FY2020-Q1RestatedAnnual report
「The Group's total research and development expenditure for the three months ended the first quarter was ¥3.485 billion. There was no material change in the status of the Group's research and development activities during the three months ended the first quarter.」
Disclosed research and development expenditure of ¥3.485 billion for the three months ended the first quarter, with no material change in research and development activities. - FY2019AdvancedAnnual report
「For the fiscal year, the Group's total research and development expenditure was ¥14.562 billion and it had 807 research personnel. During the fiscal year, 214 patents were filed in Japan, and 97 patents were registered in Japan, including utility models.」
Disclosed research and development expenditure of ¥14.562 billion, 807 research personnel, and 214 domestic patent applications and 97 registrations. - FY2019-Q3RestatedAnnual report
「The Group's total research and development expenditure for the nine months ended the third quarter was ¥11.394 billion. There was no material change in the status of the Group's research and development activities during the nine months ended the third quarter.」
Disclosed research and development expenditure of ¥11.394 billion for the nine months ended the third quarter, with no material change in research and development activities. - FY2019-Q2RestatedAnnual report
「The Group's total research and development expenditure for the six months ended the second quarter was ¥7.802 billion. There was no material change in the status of the Group's research and development activities during the six months ended the second quarter.」
Disclosed research and development expenditure of ¥7.802 billion, with no material change in research and development activities. - FY2019-Q1RestatedAnnual report
「The Group's total research and development expenditure for the three months ended the first quarter was ¥3.920 billion. There was no material change in the status of the Group's research and development activities during the three months ended the first quarter.」
Disclosed research and development expenditure of ¥3.920 billion, with no material change in research and development activities. - FY2018-Q3RestatedAnnual report
「The Group's total research and development expenditure for the nine months ended the third quarter was ¥10.219 billion. There was no material change in the status of the Group's research and development activities during the nine months ended the third quarter.」
Research and development expenditure for the nine months ended the third quarter was ¥10.219 billion, with no material change in research and development activities. - FY2018-Q2RestatedAnnual report
「The Group's total research and development expenditure for the six months ended the second quarter was ¥6.753 billion. There was no material change in the status of the Group's research and development activities during the six months ended the second quarter.」
Research and development expenditure for the six months ended the second quarter was ¥6.753 billion, with no material change in research and development activities. - FY2018-Q1RestatedAnnual report
「The Group's total research and development expenditure for the three months ended the first quarter was ¥3.390 billion. There was no material change in the status of the Group's research and development activities during the three months ended the first quarter.」
Research and development expenditure for the three months ended the first quarter was ¥3.390 billion, with no material change in research and development activities. - FY2017AdvancedAnnual report
「For the fiscal year, the Group's total research and development expenditure was ¥13.025 billion and it had 787 research personnel. During the fiscal year, 243 patents were filed in Japan, and 163 patents were registered in Japan, including utility models.」
Disclosed research and development expenditure of ¥13.025 billion, 787 research personnel, and 243 domestic patent applications and 163 registrations, and also opened an overseas research and development center in Singapore. - FY2017-Q3RestatedAnnual report
「The Group's total research and development expenditure for the nine months ended the third quarter was ¥9.625 billion. There was no material change in the status of the Group's research and development activities during the nine months ended the third quarter.」
Research and development expenditure for the nine months ended the third quarter was ¥9.625 billion, with no material change in research and development activities. - FY2017-Q2RestatedAnnual report
「The Group's total research and development expenditure for the six months ended the second quarter was ¥6.504 billion. There was no material change in the status of the Group's research and development activities during the six months ended the second quarter.」
Research and development expenditure for the six months ended the second quarter was ¥6.504 billion, with no material change in research and development activities. - FY2017-Q1First statedAnnual report
「The Group's total research and development expenditure for the three months ended the first quarter was ¥3.286 billion.」
Group-wide research and development expenditure for the three months ended the first quarter was ¥3.286 billion, with no material change in research and development activities.